retatrutide type 2 diabetes trial nct Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA A new clinical trial from

GLP-1 medications mimic the GLP-1 hormone

Weight-Loss Drug (GLP-1) Lawsuits: Eligibility, Injuries, MDL 3094 Status & 2026 Outlook Last updated: September 21, 2025 Claims tied to GLP-1 medicationsOzempic, Wegovy, Rybelsus (semaglutide) and Mounjaro/Zepbound (tirzepatide)are accelerating around gastrointestinal injuries (including ileus and alleged gastroparesis) and, more recently, vision-loss events such as NAION

1 Rubio M, et al

Blood sugar regulation muscle is the primary site for glucose disposal

Goldman Sachs Research estimates that GLP-1 obesity drug prescriptions could reach 30 million Americans by 2028 if coverage barriers are resolved, representing USD 150+ billion in additional annual market potential beyond current diabetes-only prescribing

Through these offerings, Bayer aims to support energy and skeletal health across global populations